Trials / Completed
CompletedNCT00162799
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- J. Uriach and Company · Industry
- Sex
- All
- Age
- 35 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.
Detailed description
Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled. Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days Washout period: 30 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Triflusal (DCI) |
Timeline
- Start date
- 2002-07-01
- Completion
- 2004-12-01
- First posted
- 2005-09-13
- Last updated
- 2006-06-23
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00162799. Inclusion in this directory is not an endorsement.